Sedative Drugs of Choice in Trauma Unit
For rapid sequence intubation in adult trauma patients, ketamine (1-2 mg/kg) and etomidate (0.2-0.3 mg/kg) are both acceptable first-line sedatives with equivalent mortality outcomes, though ketamine is increasingly preferred in hemodynamically unstable patients due to its sympathomimetic properties. 1
Primary Recommendation Based on 2023 Guidelines
The Society of Critical Care Medicine's 2023 guidelines provide a conditional recommendation that there is no difference between etomidate and other induction agents (including ketamine) with respect to mortality, hypotension, or vasopressor use (moderate quality evidence). 1 This represents the highest quality guideline evidence available and should frame your approach.
Key Evidence on Mortality
- Cochrane meta-analysis (n=772): No increased mortality with etomidate versus other agents (OR 1.17; 95% CI 0.86-1.60) 1
- Trauma-specific studies: No mortality difference between etomidate and ketamine in major trauma patients (19% vs 19% mortality in prehospital setting; 20% vs 17% hospital mortality in institutional protocol change study) 1
- Recent retrospective trauma data (2023): No significant difference in final mortality between ketamine (16.1%) and etomidate (20.6%) after propensity matching 2
Drug Selection Algorithm
For Hemodynamically Stable Trauma Patients:
- Either ketamine (1-2 mg/kg) OR etomidate (0.2-0.3 mg/kg) are appropriate
- Etomidate offers slightly more hemodynamic stability in this population
- Consider reducing etomidate to 0.15 mg/kg if any hemodynamic concerns 1
For Hemodynamically Unstable Trauma Patients (SBP <90 mmHg):
- Ketamine (1-2 mg/kg) is preferred due to sympathomimetic properties
- Avoid propofol - causes most profound hypotension 1
- Avoid midazolam - potent venodilator with longer onset 1
- Etomidate remains acceptable but use reduced dose (0.15 mg/kg) 1
Critical Caveat for Ketamine:
In critically ill trauma patients with depleted catecholamine stores (prolonged shock, severe hemorrhage), ketamine can paradoxically cause hypotension and cardiac arrest. 1 In these extreme cases, low-dose etomidate may be safer despite theoretical adrenal concerns.
Pharmacologic Considerations
Etomidate:
- Favorable hemodynamic profile in most patients
- Inhibits 11-beta-hydroxylase (adrenal suppression concern)
- Single-dose use for RSI does NOT increase mortality based on best evidence 1
- Dose: 0.2-0.3 mg/kg (reduce to 0.15 mg/kg if hemodynamically compromised)
Ketamine:
- Quick onset, short duration
- Preserves respiratory drive
- Sympathomimetic properties beneficial in shock
- Risk of hypotension only in catecholamine-depleted states
- Dose: 1-2 mg/kg
Propofol:
- Quick onset but most profound hypotensive effect
- Should be avoided in trauma patients requiring RSI 1
- May be acceptable only in completely stable patients without any shock risk
Midazolam:
- Longer onset than ketamine/etomidate
- Potent venodilator at RSI doses
- Not recommended for trauma RSI 1
Common Pitfalls to Avoid
Over-concern about etomidate's adrenal effects: The 2023 guidelines clarify that single-dose etomidate for RSI does not increase mortality, despite theoretical adrenal suppression 1
Assuming ketamine is always hemodynamically neutral: In severely depleted patients (prolonged shock, massive hemorrhage), ketamine can cause cardiovascular collapse 1
Using propofol in unstable trauma patients: This is the agent most likely to cause peri-intubation hypotension and should be avoided 1
Inadequate dosing: Use full induction doses (ketamine 1-2 mg/kg, etomidate 0.2-0.3 mg/kg) for first-pass success
Maintenance Sedation
While the question focuses on induction, maintenance sedation typically involves ketamine and midazolam combinations with fentanyl for ongoing sedation in intubated trauma patients. 3 However, protocols vary considerably between services, and this represents an area needing further standardization.
Practice Variation Note
Real-world practice shows emergency physicians increasingly favor ketamine while anesthesiologists continue using both etomidate and propofol more frequently. 4 The 2023 guidelines support either ketamine or etomidate as equivalent choices, allowing institutional preference while emphasizing hemodynamic status as the key decision point. 1